{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:14:12Z","timestamp":1793229252203,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd006629","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2010,12,8]],"date-time":"2010-12-08T00:00:00Z","timestamp":1291766400000}}],"reference-count":284,"publisher":"Wiley","issue":"2","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006629.pub2","type":"journal-article","created":{"date-parts":[[2010,11,29]],"date-time":"2010-11-29T19:48:45Z","timestamp":1291060125000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems"],"prefix":"10.1002","volume":"2013","author":[{"given":"Anitha","family":"Mukundan","sequence":"first","affiliation":[{"name":"Horton Park Centre; City Mental Health Team; Horton Park Avenue Bradford UK BD7 3EG"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Faulkner","sequence":"additional","affiliation":[{"name":"University of Toronto; Faculty of Kinesiology and Physical Education; 55 Harbord St Toronto Canada On M5S 2W6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Cohn","sequence":"additional","affiliation":[{"name":"Centre for Addiction and Mental Health; Schizophrenia Program and MAPS; 1001 Queen Street West Toronto Ontario Canada M6J1H4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Remington","sequence":"additional","affiliation":[{"name":"University of Toronto; Centre for Addiction and Mental Health; 250 College St Toronto Ontario Canada M5T 1R8"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,12,8]]},"reference":[{"issue":"4","key":"10.1002\/14651858.CD006629.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00213-002-1344-3","article-title":"Switching patients to aripiprazole from other antipsychotic agents: A multicenter randomized study","volume":"166","author":"Casey","year":"2003","journal-title":"Psychopharmacology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006629.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"S292","DOI":"10.1016\/S0924-977X(02)80418-7","article-title":"Switching to aripiprazole monotherapy","volume":"12","author":"Medori","year":"2002","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006629.pub2-BIB0003|cit3","first-page":"41","article-title":"Weight gain and prolactin levels in patients on long-term antipsychotic medication: a double-blind comparative trial of haloperidol decanoate and fluphenazine decanoate","volume":"1","author":"Cookson","year":"1986","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0004|cit4","unstructured":"Eli Lilly Company Comparison of continuing olanzapine to switching to quetiapine in overweight or obese patients with schizophrenia and schizoaffective disorder Eli Lilly and Company Clinical Trial Registry 2004"},{"issue":"7","key":"10.1002\/14651858.CD006629.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.4088\/JCP.v69n0702","article-title":"A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine","volume":"69","author":"Newcomer","year":"2008","journal-title":"Journal of Clinical Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD006629.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/01.jcp.0000222513.63767.de","article-title":"A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia","volume":"26","author":"Alvarez","year":"2006","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"8","key":"10.1002\/14651858.CD006629.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.pnpbp.2006.05.010","article-title":"Improvement in social functioning in outpatients with schizophrenia with prominent negative symptoms treated with olanzapine or risperidone in a 1 year randomized, open-label trial","volume":"30","author":"Ciudad","year":"2006","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD006629.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4088\/JCP.v66n0208","article-title":"Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder","volume":"66","author":"Brar","year":"2005","journal-title":"Journal of Clinical Psychiatry"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006629.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"S184","DOI":"10.1016\/S0924-977X(06)70072-4","article-title":"CATIE trial results","volume":"16","author":"Lieberman","year":"2006","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0010|cit10","unstructured":"Stroup TS Comparison of ziprasidone versus other atypical drugs in prospectively defined, unresponsive patients Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25, Toronto, Canada 2006"},{"issue":"4","key":"10.1002\/14651858.CD006629.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1176\/ajp.2006.163.4.611","article-title":"Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic","volume":"163","author":"Stroup","year":"2006","journal-title":"American Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD006629.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00213-006-0564-3","article-title":"Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine","volume":"189","author":"Chrzanowski","year":"2006","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0013|cit13","first-page":"354","article-title":"Weight with clozapine as compared to conventional antipsychotic medications","volume":"1, 2 & 3","author":"Covell","year":"1999","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0014|cit14","unstructured":"Ducate S Pondrom M Thivierge S Patel H Switching to ziprasidone in correctional inpatients: Efficacy and safety Proceedings of the 156th Annual meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California USA 2003"},{"issue":"2","key":"10.1002\/14651858.CD006629.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1017\/S1461145705005067","article-title":"Effects of quetiapine and haloperidol on body mass index and glycaemic control: a long-term, randomized, controlled trial","volume":"8","author":"Emsley","year":"2005","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD006629.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4088\/JCP.v64n0203","article-title":"Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia","volume":"64","author":"Godleski","year":"2003","journal-title":"Journal of Clinical Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD006629.pub2-BIB0017|cit17","first-page":"168","article-title":"The effect of quetiapine on different domains of cognition and negative symptoms in schizophrenia","volume":"67","author":"Horacek","year":"2004","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0018|cit18","unstructured":"Horacek J Seifertova D Janu L Petranova T The effect of quetiapine on different domains of cognition and negative symptoms in schizophrenia Proceedings of the 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7-13; Davos, Switzerland 2004"},{"issue":"1","key":"10.1002\/14651858.CD006629.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S0920-9964(03)80469-3","article-title":"Olanzapine and risperidone in schizophrenia: a randomized double-blind crossover study","volume":"60","author":"Irwin","year":"2003","journal-title":"Schizophrenia Research"},{"issue":"1","key":"10.1002\/14651858.CD006629.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"120","DOI":"10.4088\/JCP.v65n0121","article-title":"Guidelines for the use of long-acting injectable atypical antipsychotics","volume":"65","author":"Kane","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0021|cit21","unstructured":"Kane JM Ziprasidone\u2019s long-term efficacy in treatment- refractory schizophrenia Proceedings of the 158th Annual Meeting of the American Psychiatric Association; 2005 May 21-26; Atlanta, Georgia, USA 2005"},{"issue":"2","key":"10.1002\/14651858.CD006629.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4088\/JCP.v68n0206","article-title":"Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine","volume":"68","author":"Kane","year":"2007","journal-title":"Journal of Clinical Psychiatry"},{"issue":"3-4","key":"10.1002\/14651858.CD006629.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1023\/B:ACLI.0000008171.90644.f8","article-title":"Adverse effects and laboratory parameters of high-dose olanzapine vs. clozapine in treatment-resistant schizophrenia","volume":"15","author":"Kelly","year":"2003","journal-title":"Annals of Clinical Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD006629.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/JCP.0b013e3180a9076c","article-title":"Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain","volume":"27","author":"Kim","year":"2007","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0025|cit25","unstructured":"Kinon B Basson B Malcolm S Breier A Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine Proceedings of the 39th Annual Meeting of the New Clinical Drug Evaluation Unit; 1999 Jun 1-4; Boca Raton, Florida, USA 1999"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0026|cit26","doi-asserted-by":"crossref","unstructured":"Kinon B Breier A Malcolm S Basson B Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine 11th World Congress of Psychiatry; 1999 Aug 6-11; Hamburg, Germany 1999","DOI":"10.4088\/JCP.v61n1105"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0027|cit27","doi-asserted-by":"crossref","unstructured":"Kinon BJ Basson B Wang J Malcolm SK Stauffer VL Rapid reduction in hyperprolactinemia upon switching treatment to olanzapine from conventional antipsychotic drugs or risperidone Proceedings of the 40th Annual Meeting of the New Clinical Drug Evaluation Unit; 2000 May 30 - Jun 2; Boca Raton, Florida, USA 2000","DOI":"10.1016\/S0924-977X(00)80349-1"},{"issue":"11","key":"10.1002\/14651858.CD006629.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"833","DOI":"10.4088\/JCP.v61n1105","article-title":"Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine","volume":"61","author":"Kinon","year":"2000","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0029|cit29","unstructured":"Kinon BJ Basson BR Wang J Malcolm SK Stauffer VL Rapid reduction in hyperprolactinemia Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18; Chicago, Illinois, USA 2000"},{"issue":"5","key":"10.1002\/14651858.CD006629.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.psyneuen.2005.12.006","article-title":"Improvement in hyperprolactinemia and reproductive co-morbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine","volume":"31","author":"Kinon","year":"2006","journal-title":"Psychoneuroendocrinology"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1196\/annals.1314.043","article-title":"Longitudinal effect of olanzapine on fasting serum lipids: a randomized, prospective, 4-month study","volume":"1032","author":"Kinon","year":"2004","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"7","key":"10.1002\/14651858.CD006629.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"569","DOI":"10.4088\/JCP.v63n0706","article-title":"Switching to olanzapine from previous antipsychotics: a regional collaborative multicenter trial assessing 2 switching techniques in Asia Pacific","volume":"63","author":"Lee","year":"2002","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0033|cit33","unstructured":"Emsley RA Bailey P Jones AM Raniwalla J Efficacy of quetiapine fumarate in partial responders Proceedings of the 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15-20; Washington DC, USA 1999"},{"issue":"3","key":"10.1002\/14651858.CD006629.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0924-977X(01)80314-X","article-title":"Patterns of response in patients with schizophrenia partially responsive to fluphenazine and switched to quetiapine or haloperidol","volume":"11","author":"Nasrallah","year":"2001","journal-title":"European Neuropsychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD006629.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0924-977X(01)80315-1","article-title":"Switching from fluphenazine to quetiapine ameliorates extrapyramidal symptoms and neuroendocrine side effects in patients with schizophrenia","volume":"11","author":"Weiden","year":"2001","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0036|cit36","unstructured":"Newcomer JW L'Italien G Vester-Blokland McQuade RD Carson WH Marcus RN Improvement of non-hdl cholesterol levels among patients randomized to aripiprazole versus olanzapine Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25, Toronto, Canada 2006"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0037|cit37","unstructured":"O'Halloran RA Hodge A Kim K-S Habil MHH Barahona A Vargas MT Woodbury MA Comparison of olanzapine and quetiapine treatments for schizophrenia Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA 2003"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006629.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"S291","DOI":"10.1016\/S0924-977X(00)80313-2","article-title":"Longer-term effects of switching from typical to atypical antipsychotics in patients with stable schizophrenia","volume":"10","author":"Robinson","year":"2000","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0039|cit39","unstructured":"Corey-Lisle P Kolotkin RL Crosby RD L'Italien G Changes in weight and weight-related quality of life in aripiprazole versus standard-of-care treatment Proceedings of the 14th Congress of the Association of European Psychiatrists; 2006 March 4-8; Nice, France 2006"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0040|cit40","unstructured":"Hanssens L L'Italien G Marcus RN McQuade RD Carson WH Beuzen J-N Reasons for switching among community-treated schizophrenic patients in a naturalistic setting: schizophrenia trial of aripiprazole: STAR study Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25, Toronto, Canada 2006"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0041|cit41","unstructured":"L'Italien G Hanssens L Marcus RN McQuade RD Carson WH Beuzen J-N Metabolic effects of aripiprazole versus standard of care (the STAR trial) Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25, Toronto, Canada 2006"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0042|cit42","unstructured":"McQuade R Radhakrishnan M Stock E Lam S Iwamoto T Pans M Carson W Investigator assessment of clinical parameters after initiating aripiprazole therapy Proceedings of the 158th Annual Meeting of the American Psychiatric Association; 2005 May 21-26, Atlanta, GA, USA 2005"},{"issue":"1","key":"10.1002\/14651858.CD006629.pub2-BIB0043|cit43","first-page":"157","article-title":"Broad effectiveness trial with aripiprazole","volume":"67","author":"Riera","year":"2004","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0044|cit44","unstructured":"Riera L Tandon R Stock EG Kujawa MJ Torbeyns AF Borian FE McQuade RD IwamotoT Broad Effectiveness Trial with Aripiprazole Proceedings of the Twelfth Biennial Winter Workshop on Schizophrenia; 2004 Feb 7-13; Davos Switzerland 2004"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00213-005-0205-2","article-title":"A crossover study on lipid and weight changes associated with olanzapine and risperidone","volume":"183","author":"Su","year":"2005","journal-title":"Psychopharmacology"},{"issue":"7","key":"10.1002\/14651858.CD006629.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jpsychires.2006.03.008","article-title":"Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study","volume":"40","author":"Wang","year":"2006","journal-title":"Journal of Psychiatric Research"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD006629.pub2-BIB0047|cit47","first-page":"160","article-title":"Effects of oral ziprasidone on weight and serum lipids in patients with schizophrenia","volume":"53","author":"Cutler","year":"2002","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0048|cit48","first-page":"S265","article-title":"Improvement in markers of health status 6 weeks after switching from olanzapine to ziprasidone","volume":"9","author":"Daniel","year":"1999","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0049|cit49","first-page":"S265","article-title":"Switching from olanzapine to ziprasidone: an interim analysis of a 6-week study","volume":"9","author":"Daniel","year":"1999","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0050|cit50","unstructured":"Daniel DG Lieberman JA Birnbaum RJ Improvement in markers of health status six weeks after switching from olanzapine to ziprasidone Proceedings of the 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15-20; Washington DC, USA 1999"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0051|cit51","unstructured":"Daniel DG Weiden P O'Sullivan RL Improvement in indices of health status in outpatients with schizophrenia following a switch to ziprasidone from conventional antipsychotics, olanzapine or risperidone Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18; Chicago, Illinois, USA 2000"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0052|cit52","unstructured":"Daniel DG Weiden P O'Sullivan RL Improvement in indices of health status in outpatients with schizophrenia following a switch to ziprasidone from conventional antipsychotics, olanzapine or risperidone Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA 2002"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0053|cit53","unstructured":"Romano SJ Cutler NR Weiden PJ Simpson GM Ziprasidone's effects on weight and lipids in patients with schizophrenia Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA 2002"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"S264","DOI":"10.1016\/S0924-977X(99)80276-4","article-title":"Switching from conventional antipsychotics to ziprasidone: an interim analysis of a 6-week study","volume":"9","author":"Weiden","year":"1999","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"issue":"6","key":"10.1002\/14651858.CD006629.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/01.jcp.0000095347.32154.08","article-title":"Improvement in indices of health status In outpatients with schizophrenia switched to ziprasidone","volume":"23","author":"Weiden","year":"2003","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0056|cit56","unstructured":"Weiden PJ Kramer TAM Harvey PD Powchik P Simpson GM Switch Study Group Switching from conventional antipsychotics to ziprasidone: an interim analysis of a six-week study Proceedings of the 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15-20; Washington DC, USA 1999"},{"issue":"5","key":"10.1002\/14651858.CD006629.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/sj.npp.1301482","article-title":"Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone","volume":"33","author":"Weiden","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"580","DOI":"10.4088\/JCP.v64n0514","article-title":"Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia","volume":"64","author":"Weiden","year":"2003","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0059|cit59","doi-asserted-by":"crossref","unstructured":"Weiden PJ Weiden PJ Daniel DG Simpson G Romano SJ Health status in stable patients switched to ziprasidone Proceedings of the 12th World Congress of Psychiatry; 2002 Aug 24-29; Yokohama, Japan 2002","DOI":"10.1016\/S0924-9338(02)80453-9"},{"issue":"4","key":"10.1002\/14651858.CD006629.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/JCP.0b013e3180a9076c","article-title":"Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain","volume":"27","author":"Kim","year":"2007","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD006629.pub2-BIB0061|cit61","first-page":"182","article-title":"A control study of weight gain caused by chlorpromazine, clozapine and sulpiride in schizophrenics","volume":"10","author":"Zhang","year":"2004","journal-title":"Journal of Clinical Psychosomatic Diseases"},{"issue":"13","key":"10.1002\/14651858.CD006629.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jpsychires.2008.01.004","article-title":"Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia","volume":"42","author":"Ader","year":"2008","journal-title":"Journal of Psychiatric Research"},{"issue":"1","key":"10.1002\/14651858.CD006629.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.schres.2009.10.012","article-title":"Prevention of antipsychotic-induced weight gain with early behavioural intervention in first-episode psychosis: 2-year results of a randomized controlled trial","volume":"116","author":"Alvarez-Jimenez","year":"2010","journal-title":"Schizophrenia Research"},{"issue":"8","key":"10.1002\/14651858.CD006629.pub2-BIB0064|cit64","first-page":"1130","article-title":"A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents","volume":"29","author":"Arman","year":"2008","journal-title":"Saudi Medical Journal"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0065|cit65","first-page":"294","article-title":"A non-pharmacological intervention for weight gain management for patients with schizophrenia: Multicentric, randomized controlled clinical trial-are modest effects important for challenging outcomes","volume":"1","author":"Attux","year":"2011","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0066|cit66","first-page":"24","article-title":"Metformin and impaired glucose tolerance in overweight persons with schizophrenia","volume":"1","author":"Ballon","year":"2011","journal-title":"Schizophrenia Bulletin"},{"issue":"1-2","key":"10.1002\/14651858.CD006629.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.psychres.2008.01.011","article-title":"Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study","volume":"159","author":"Baptista","year":"2008","journal-title":"Psychiatry Research"},{"issue":"1","key":"10.1002\/14651858.CD006629.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1055\/s-0028-1085438","article-title":"Rosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: a pilot double-blind, placebo-controlled, 12-week trial","volume":"42","author":"Baptista","year":"2009","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0069|cit69","unstructured":"Barak N Betahistine safely mitigates olanzapine adverse: Role of histamine receptors in weight gain and somnolence Proceedings of the 163rd Annual Meeting of the American Psychiatric Association; 2010 May 22-26; New Orleans, LA 2010"},{"issue":"2-3","key":"10.1002\/14651858.CD006629.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.schres.2010.02.410","article-title":"Sibutramine in the treatment of antipsychotic-induces weight gain: a randomized, placebo-controlled double-blind study","volume":"117","author":"Biedermann","year":"2010","journal-title":"Schizophrenia Research"},{"issue":"2","key":"10.1002\/14651858.CD006629.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.psychres.2011.07.008","article-title":"Prediction of long-term metabolic effects of olanzapine and risperidone treatment from baseline body mass index in schizophrenia and bipolar disorder","volume":"189","author":"Bobo","year":"2011","journal-title":"Psychiatry Research"},{"issue":"5","key":"10.1002\/14651858.CD006629.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1097\/JCP.0b013e31822bb573","article-title":"placebo-controlled pilot study of ramelteon for adiposity and lipids in patients with schizophrenia","volume":"31","author":"Borba","year":"2011","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"7","key":"10.1002\/14651858.CD006629.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1176\/ps.62.7.pss6207_0800","article-title":"Weight loss intervention for people with serious mental illness: A randomized controlled trial of the renew program","volume":"62","author":"Brown","year":"2011","journal-title":"Psychiatric Services"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0074|cit74","unstructured":"Buchanan RW Boggs DL Conley RR Gorelick DA McMahon RP Gold JM A pilot study evaluating the cognitive effects of rimonabant in people with schizophrenia Proceedings of the 50th Annual Meeting of the American College of Neuropsychopharmacology; 2011 Dec 4-8; Waikoloa, Hawaii 2011"},{"issue":"3","key":"10.1002\/14651858.CD006629.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/sj.npp.1300089","article-title":"Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients","volume":"28","author":"Bustillo","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0076|cit76","unstructured":"Capra C Effects of a nutritional supplement on weight gain after initiation of atypical antipsychotic medication in early psychosis patients Australian New Zealand Clinical Trials Registry 2009"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0077|cit77","unstructured":"Carina C Effects of a nutritional supplement on weight gain after initiation of atypical antipsychotic medication in early psychosis patients Australian New Zealand Clinical Trials Registry 2009"},{"issue":"3","key":"10.1002\/14651858.CD006629.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/JCP.0b013e3181a289cb","article-title":"Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg\/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration","volume":"29","author":"Citrome","year":"2009","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD006629.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/00004714-200206000-00003","article-title":"Antipsychotic-induced weight gain and therapeutic response: a differential association","volume":"22","author":"Czobor","year":"2002","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0080|cit80","first-page":"S1181","article-title":"A 16-week, multicentre, randomized, open-label study assessing effects of aripiprazole versus other atypicals for schizophrenia patients with metabolic syndrome","volume":"24","author":"Day-Poulsen","year":"2009","journal-title":"Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24-28; Lisbon Portugal"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0081|cit81","doi-asserted-by":"crossref","unstructured":"Deberdt W Trzaskoma Q Carlson C Bymaster F Winokur A Floris M Amantadine for weight gain in olanzapine-treated patients Proceedings of the Thematic Conference of the World Psychiatric Association on \"Treatments in Psychiatry: An Update\"; 2004 Nov 10-13; Florence, Italy 2004","DOI":"10.1016\/j.euroneuro.2004.03.005"},{"issue":"4","key":"10.1002\/14651858.CD006629.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2147\/TCRM.S3153","article-title":"double-blind, randomized trial comparing efficacy and safety of continuing olanzapine versus switching to quetiapine in overweight or obese patients with schizophrenia or schizoaffective disorder","volume":"4","author":"Deberdt","year":"2008","journal-title":"Therapeutics and Clinical Risk Management"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006629.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"S467","DOI":"10.1016\/S0924-977X(07)70711-3","article-title":"Weight gain associated with olanzapine and first generation antipsychotics: results from a pragmatic randomized controlled trial","volume":"17","author":"Lima","year":"2007","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"S435","DOI":"10.1016\/S0924-977X(08)70638-2","article-title":"Olanzapine long-acting injection in patients with schizophrenia at risk of relapse: 12-week switching data","volume":"18","author":"Detke","year":"2008","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0085|cit85","unstructured":"Eli LandC The comparison of efficacy and safety of continuing olanzapine to switching to quetiapine in overweight or obese patients with schizophrenia or schizoaffective disorder Eli Lilly and Company Clinical Trial Registry 2007"},{"issue":"5","key":"10.1002\/14651858.CD006629.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1185\/030079908X297385","article-title":"Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia","volume":"24","author":"Faries","year":"2008","journal-title":"Current Medical Research and Opinion"},{"issue":"10","key":"10.1002\/14651858.CD006629.pub2-BIB0087|cit87","first-page":"S258","article-title":"Efficacy and safety of a lifestyle balance program for antipsychotic medication associated obesity","volume":"3","author":"Firestone","year":"2011","journal-title":"PM and R"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"S447","DOI":"10.1016\/S0924-977X(08)70660-6","article-title":"Long-term effect on weight of aripiprazole-clozapine in schizophrenia patients with suboptimal response on clozapine","volume":"18","author":"Fleischhacker","year":"2008","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1016\/j.eurpsy.2008.01.784","article-title":"Weight change on aripiprazole-clozapine combination in schizophrenic patients with weight gain and suboptimal response on clozapine: 16-week double-blind study","volume":"23","author":"Fleischhacker","year":"2008","journal-title":"European Psychiatry"},{"issue":"8","key":"10.1002\/14651858.CD006629.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1017\/S1461145710000490","article-title":"Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: A randomized, double-blind, placebo-controlled trial","volume":"13","author":"Fleischhacker","year":"2010","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1741-7015-6-17","article-title":"Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded study","volume":"6","author":"Ganguli","year":"2008","journal-title":"BMC Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006629.pub2-BIB0092|cit92","first-page":"S44","article-title":"Behavioural intervention for weight loss in schizophrenia: An rct with active controls","volume":"5","author":"Ganguli","year":"2011","journal-title":"Indian Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1499-2671(11)52059-3","article-title":"Weight reduction in schizophrenia, by lifestyle change: A randomized clinical trial","volume":"2","author":"Ganguli","year":"2011","journal-title":"Canadian Journal of Diabetes"},{"issue":"7","key":"10.1002\/14651858.CD006629.pub2-BIB0094|cit94","first-page":"24","article-title":"Add-on sibutramine for olanzapine-induced weight gain","volume":"11","author":"Ginsberg","year":"2004","journal-title":"Primary Psychiatry"},{"issue":"suppl 1","key":"10.1002\/14651858.CD006629.pub2-BIB0095|cit95","first-page":"152","article-title":"A placebo-controlled trial of sibutramine added to patients with olanzapine-induced weight gain","volume":"5","author":"Henderson","year":"2004","journal-title":"World Journal of Biological Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD006629.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/JCP.0b013e31819a8dbe","article-title":"Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients","volume":"29","author":"Henderson","year":"2009","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"1-3","key":"10.1002\/14651858.CD006629.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.schres.2011.04.009","article-title":"Effects of modafinil on weight, glucose and lipid metabolism in clozapine-treated patients with schizophrenia","volume":"130","author":"Henderson","year":"2011","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0098|cit98","unstructured":"Hoffmann V Case M Jacobson J Algorithms including amantadine, metformin and zonisamide for mitigation of weight gain during olanzapine treatment in outpatients with schizophrenia Proceedings of the 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16-21; San Francisco, CA 2009"},{"issue":"9","key":"10.1002\/14651858.CD006629.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/j.1365-2850.2010.01590.x","article-title":"Pilot study of the efficacy of an educational programme to reduce weight, on overweight and obese patients with chronic stable schizophrenia","volume":"17","author":"Iglesias-Garcia","year":"2010","journal-title":"Journal of Psychiatric and Mental Health Nursing"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0100|cit100","unstructured":"IRCT201009112181N5 The role of ranitidine in the prevention of olanzapine induced weight gain http:\/\/www.irct.ir\/ 2010"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0101|cit101","unstructured":"IRCT201107187049N1 An assessment of effects of melatonin on metabolic effects of olanzapine in patients with schizophrenia http:\/\/www.irct.ir\/searchresult.php?id=7049&number=1 2011"},{"issue":"5","key":"10.1002\/14651858.CD006629.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"706","DOI":"10.4088\/JCP.v69n0503","article-title":"Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week randomized, double-blind, placebo-controlled trial","volume":"69","author":"Joffe","year":"2008","journal-title":"Journal of Clinical Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD006629.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1111\/j.1742-1241.2010.02485.x","article-title":"An exploratory analysis of factors associated with weight change in a 16-week trial of oral vs. Orally disintegrating olanzapine: The platypus study","volume":"64","author":"Karagianis","year":"2010","journal-title":"International Journal of Clinical Practice"},{"issue":"2","key":"10.1002\/14651858.CD006629.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/10401230802017050","article-title":"Metabolic risk with second-generation antipsychotic treatment: a double-blind randomized 8-week trial of risperidone and olanzapine","volume":"20","author":"Kelly","year":"2008","journal-title":"Annals of Clinical Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD006629.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/JCP.0b013e318204825b","article-title":"Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia. A randomized, double-blind, pilot study","volume":"31","author":"Kelly","year":"2011","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0106|cit106","first-page":"310","article-title":"Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: A randomized, doubleblind pilot study","volume":"1","author":"Kelly","year":"2011","journal-title":"Schizophrenia Bulletin"},{"issue":"9 Suppl","key":"10.1002\/14651858.CD006629.pub2-BIB0107|cit107","first-page":"228","article-title":"Metabolic and body mass parameters observed with jnj-37822681, a novel fast-dissociating d receptor antagonist, versus olanzapine","volume":"69","author":"Kent","year":"2011","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0108|cit108","unstructured":"Kim J Yim S Nam J A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4-10; Davos, Switzerland Davos, SWITZERLAND Elsevier Science Bv 2006 86"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006629.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"S440","DOI":"10.1016\/S0924-977X(07)70666-1","article-title":"Effectiveness of switching from risperidone to amisulpride in stabilized schizophrenic patients with depression","volume":"17","author":"Kim","year":"2007","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0110|cit110","unstructured":"Kim SI Sung YM Paik KW Yun KW Kim YC Lim W The efficacy of topiramate for weight loss and psychiatric symptom severity in overweight or obese patients maintained on atypical antipsychotics Proceedings of the 160th Annual Meeting of the American Psychiatric Association; 2007 May 19-24; San Diego, CA 2007"},{"issue":"5","key":"10.1002\/14651858.CD006629.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/YIC.0b013e328356acad","article-title":"Paliperidone er versus risperidone for neurocognitive function in patients with schizophrenia: A randomized, open-label, controlled trial","volume":"27","author":"Kim","year":"2012","journal-title":"International Clinical Psychopharmacology"},{"issue":"12","key":"10.1002\/14651858.CD006629.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1176\/ajp.2006.163.12.2072","article-title":"A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents","volume":"163","author":"Klein","year":"2006","journal-title":"American Journal of Psychiatry"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006629.pub2-BIB0113|cit113","first-page":"32","article-title":"Metformin treatment of weight gain associated with antipsychotic drug therapy","volume":"11","author":"Klein","year":"2008","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"6","key":"10.1002\/14651858.CD006629.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1097\/jcp.0b013e31815a8872","article-title":"Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study","volume":"27","author":"Kluge","year":"2007","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD006629.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.psyneuen.2008.08.016","article-title":"Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever","volume":"34","author":"Kluge","year":"2009","journal-title":"Psychoneuroendocrinology"},{"issue":"4","key":"10.1002\/14651858.CD006629.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/01.wnf.0000172994.56028.c3","article-title":"Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain","volume":"28","author":"Ko","year":"2005","journal-title":"Clinical Neuropharmacology"},{"issue":"1-3","key":"10.1002\/14651858.CD006629.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.schres.2009.02.006","article-title":"Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol","volume":"110","author":"Krakowski","year":"2009","journal-title":"Schizophrenia Research"},{"issue":"4","key":"10.1002\/14651858.CD006629.pub2-BIB0118|cit118","first-page":"217","article-title":"A comparative study on the efficacy and weight gain between quetiapine and clozapine in the treatment of schizophrenia","volume":"20","author":"Kuang","year":"2007","journal-title":"Shandong Archives of Psychiatry [\u5c71\u4e1c\u7cbe\u795e\u533b\u5b66]"},{"issue":"4","key":"10.1002\/14651858.CD006629.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"547","DOI":"10.4088\/JCP.v67n0405","article-title":"Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: a 12-week randomized controlled clinical trial","volume":"67","author":"Kwon","year":"2006","journal-title":"Journal of Clinical Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD006629.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1136\/ebmh.12.2.50","article-title":"Switching to aripiprazole from olanzapine leads to weight loss in overweight people with schizophrenia or schizoaffective disorder","volume":"12","author":"Lambert","year":"2009","journal-title":"Evidence-Based Mental Health"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"S440","DOI":"10.1016\/S0924-977X(08)70647-3","article-title":"Prolactin level as an indicator to clinical psychopathological severity in aripiprazole treated schizophrenia","volume":"18","author":"Lan","year":"2008","journal-title":"European Neuropsychopharmacology"},{"issue":"9","key":"10.1002\/14651858.CD006629.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/FPC.0b013e32833ca24b","article-title":"Drd2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia","volume":"20","author":"Lencz","year":"2010","journal-title":"Pharmacogenetics and Genomics"},{"issue":"23","key":"10.1002\/14651858.CD006629.pub2-BIB0123|cit123","first-page":"2784","article-title":"Aripiprazole in the treatment of schizophrenia with diabetes caused by antipsychotic drugs of the safety study","volume":"20","author":"Li","year":"2008","journal-title":"Medical Journal of Chinese People's Health [\u4e2d\u56fd\u6c11\u5eb7\u533b\u5b66]"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0124|cit124","unstructured":"Lieberman J Jarskog LF Hamer R Catellier D Stewart D LaVange L Metformin for obesity and metabolic abnormalities in schizophrenia Proceedings of the 49th Annual meeting of the Americam College of Neuropsychopharmacology; 2010 Dec 5-9; Miami, Florida 2010"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0125|cit125","unstructured":"Linne Y Rossner S Neovius M Body composition and metabolic changes during antipsychotic treatment. A randomized trial comparing sertindole and olanzapine study design presentation Proceedings of the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders; 2008 Feb 3-7; Montreux, Switzerland 2008"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1055\/s-2007-992148","article-title":"A psychoeducational program for weight loss in patients who have experienced weight gain during antipsychotic treatment with olanzapine","volume":"41","author":"Mauri","year":"2008","journal-title":"Pharmacopsychiatry"},{"issue":"2","key":"10.1002\/14651858.CD006629.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/JCP.0b013e3182488758","article-title":"A randomized, placebo-controlled study of zonisamide to prevent olanzapine-associated weight gain","volume":"32","author":"McElroy","year":"2012","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD006629.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"318","DOI":"10.4088\/JCP.08m04267","article-title":"The moderating impact of ethnicity on metabolic outcomes during treatment with olanzapine and aripiprazole in patients with schizophrenia","volume":"70","author":"Meyer","year":"2009","journal-title":"Journal of Clinical Psychiatry"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006629.pub2-BIB0129|cit129","first-page":"26","article-title":"Antipsychotic stay vs. switch for metabolic benefit: psychiatric cost","volume":"35","author":"Meyer","year":"2009","journal-title":"Schizophrenia Bulletin"},{"issue":"5","key":"10.1002\/14651858.CD006629.pub2-BIB0130|cit130","first-page":"A17","article-title":"The effects of aripiprazole in combination with clozapine: patient functioning results from a double-blind, 16-week study in patients with schizophrenia (CN138-170)","volume":"22","author":"Millar","year":"2008","journal-title":"Journal of Psychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD006629.pub2-BIB0131|cit131","first-page":"A17","article-title":"Weight outcomes in an open-label comparision of switching strategies from risperidone to aripiprazole in patients with schizophrenia (CN138-169)","volume":"22","author":"Millar","year":"2008","journal-title":"Journal of Psychopharmacology"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0132|cit132","unstructured":"Moore N Switching to aripiprazole from other second-generation antipsychotics Australian New Zealand Clinical Trials Registry 2006"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0133|cit133","unstructured":"L'ltalien GJ Newcomer JW Berman R Marcus RN Kerselaers W McQuade RD Rates of metabolic syndrome and non-high-density lippprotein-cholesterol among overweight patients switched from olanzapine to aripiprazole (Study CN138-122) Proceedings of the 160th Annual Meeting of the American Psychiatric Association; 2007 May 19-24; San Diego, CA 2007"},{"issue":"7","key":"10.1002\/14651858.CD006629.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.4088\/JCP.v69n0702","article-title":"A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine","volume":"69","author":"Newcomer","year":"2008","journal-title":"Journal of Clinical Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD006629.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.schres.2009.05.024","article-title":"A randomized controlled trial of the effect of sublingual orally disintegrating olanzapine versus oral olanzapine on body mass index: the PLATYPUS Study","volume":"113","author":"Karagianis","year":"2009","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0136|cit136","first-page":"302","article-title":"Factors associated with weight change in a 16-week randomized double-blind, double-dummy trial of sublingual orally disintegrating olanzapine vs. oral olanzapine in patients who gained weight during olanzapine treatment: the PLATYPUS Study","volume":"1","author":"Karagianis","year":"2009","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0137|cit137","unstructured":"Stroup T A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, orrisperidone to aripiprazole to reduce metabolic risk Proceedings of the 164th annual general meeting of the American Psychiatric Association; 2011 May 14-18; Honolulu, Hawaii 2011"},{"issue":"1","key":"10.1002\/14651858.CD006629.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3371\/CSRP.1.1.6","article-title":"Comparison of Antipsychotics for Metabolic Problems (CAMP): a NIMH schizophrenia trials network study","volume":"1","author":"Stroup","year":"2007","journal-title":"Clinical Schizophrenia and Related Psychoses"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0139|cit139","unstructured":"NCT00645099 A 6 month study to compare the metabolic effects of paliperidone er and olanzapine in patients with schizophrenia http:\/\/www.clinicaltrials.gov 2008"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0140|cit140","unstructured":"NCT00690235 Demonstrate the effects of pramlintide on weight reduction in schizophrenia http:\/\/www.clinicaltrials.gov 2008"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0141|cit141","unstructured":"NCT00709202 To examine the effect of betahistine on antipsychotic induced weight gain in adolescents http:\/\/www.clinicaltrials.gov 2008"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0142|cit142","unstructured":"NCT00734435 Olanzapine given in combination with zonisamide sr to prevent weight gain in schizophrenic subjects http:\/\/www.clinicaltrials.gov 2008"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0143|cit143","unstructured":"NCT00759460 Study on metabolic parameters of sertindole in patients with schizophrenia http:\/\/www.clinicaltrials.gov 2008"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0144|cit144","unstructured":"NCT00759993 Chromium piccolinate in the prevention of weight gain induced by serotonergic medications initiated on psychiatric inpatient units http:\/\/www.clinicaltrials.gov 2008"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0145|cit145","unstructured":"NCT00793780 Pilot trial of naltrexone for obesity in women with schizophrenia http:\/\/www.clinicaltrials.gov 2008"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0146|cit146","unstructured":"NCT00806234 Reducing weight gain and improving metabolic function in children being treated with antipsychotics http:\/\/www.clinicaltrials.gov 2008"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0147|cit147","unstructured":"NCT00816907 The use of metformin in the treatment of antipsychotic-induced weight gain in schizophrenia (The METS Study) http:\/\/www.clinicaltrials.gov 2009"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0148|cit148","unstructured":"NCT00845507 Exenatide for the treatment of weight gain associated with olanzapine in obese adults http:\/\/ClinicalTrials.gov\/show\/NCT00845507 2008"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0149|cit149","unstructured":"NCT00857818 Metabolic abnormalities - OPT http:\/\/www.clinicaltrials.gov 2009"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0150|cit150","unstructured":"NCT00902694 Examining an exercise and nutrition program for reducing weight in people with severe mental illnesses (the achieve study) http:\/\/ClinicalTrials.gov\/show\/NCT00902694 2009"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0151|cit151","unstructured":"NCT00934908 Prevention of weight gain and dyslipidemia by green tea in patients initiating therapy with olanzapine http:\/\/www.clinicaltrials.gov 2009"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0152|cit152","unstructured":"NCT00990925 Lifestyle modification for weight loss in schizophrenia http:\/\/www.clinicaltrials.gov 2009"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0153|cit153","unstructured":"NCT01052714 Healthy lifestyles for mentally ill people who have experienced weight gain from their antipsychotic medications - 2 http:\/\/www.clinicaltrials.gov 2010"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0154|cit154","unstructured":"NCT01075295 Prevention of weight gain in early schizophrenia and schizoaffective disorder http:\/\/www.clinicaltrials.gov 2010"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0155|cit155","unstructured":"NCT01167348 The effectiveness of auricular acupressure on bodybweight parameters on patients with schizophrenia http:\/\/ClinicalTrials.gov\/show\/NCT01167348 2010"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0156|cit156","unstructured":"NCT01272752 Anti-psychotic medication (new use) weight loss study http:\/\/ClinicalTrials.gov\/show\/NCT01272752 2011"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0157|cit157","unstructured":"NCT01272765 Anti-psychotic medication (stable dose) weight loss study http:\/\/ClinicalTrials.gov\/show\/NCT01272765 2011"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0158|cit158","unstructured":"NCT01295372 Safety and efficacy of zicronapine in patients with schizophrenia http:\/\/ClinicalTrials.gov\/show\/NCT01295372 2011"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0159|cit159","unstructured":"NCT01300637 Effects of adjunctive metformin on metabolic profiles in clozapine-treated schizophrenic patients http:\/\/ClinicalTrials.gov\/show\/NCT01300637 2011"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0160|cit160","unstructured":"NCT01324973 Web-based weight management for individuals with mental illness http:\/\/ClinicalTrials.gov\/show\/NCT01324973 2011"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0161|cit161","unstructured":"NCT01491490 Treatment on iatrogenic weight gain and dyslipidaemia associated with olanzapine http:\/\/ClinicalTrials.gov\/show\/NCT01491490 2011"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0162|cit162","unstructured":"NCT01567124 Alleviating the metabolic side effects of antipsychotic medications http:\/\/ClinicalTrials.gov\/show\/NCT01567124 2012"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0163|cit163","unstructured":"NCT01593774 Melatonin for prevention of metabolic side effects of olanzapine http:\/\/ClinicalTrials.gov\/show\/NCT01593774 2012"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0164|cit164","unstructured":"Newcomer JW Haupt DW Fahnestock PA Flavin KS Nicol GE Schweiger JA Changes in adiposity, insulin sensitivity and lipid metabolism during randomized antipsychotic treatment in schizophrenia Proceedings of the 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16-21; San Francisco, CA 2009"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006629.pub2-BIB0165|cit165","first-page":"488","article-title":"Changes in adiposity, insulin sensitivity and related metabolic measures during randomized medication switches to aripiprazole from other atypical antipsychotics","volume":"59","author":"Newcomer","year":"2010","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0166|cit166","unstructured":"Nicol G Haupt DW Yingling MD Fahnestock PA Flavin KS Schweiger JA Changes in adiposity and metabolic measures during medication switches to aripiprazole from other atypical antipsychotics Proceedings of the 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16-21; San Francisco, CA 2009"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0167|cit167","unstructured":"Oliveira AVG Ganho de peso em pacientes em uso de olanzapina e antipsic\u00f3ticos t\u00edpicos: um ensaio cl\u00ednico randomizado PhD thesis 2005"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0168|cit168","unstructured":"Pae C-U Lim H-K Patkar AA Masand P Lee C Paik I-H Switching strategies to aripiprazole from other antipsychotics in stabilized schizophrenia: a randomized, 12 week, open label, parallel group study Proceedings of the 160th Annual Meeting of the American Psychiatric Association; 2007 May 19-24; San Diego, CA 2007"},{"issue":"1-3","key":"10.1002\/14651858.CD006629.pub2-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.schres.2007.10.022","article-title":"Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naive population","volume":"99","author":"Perez-Iglesias","year":"2008","journal-title":"Schizophrenia Research"},{"issue":"3","key":"10.1002\/14651858.CD006629.pub2-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/JCP.0b013e318172b8e6","article-title":"Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment","volume":"28","author":"Perez-Iglesias","year":"2008","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006629.pub2-BIB0171|cit171","first-page":"141","article-title":"Predictors of antipsychotic-induced weight gain after the first 3 years of treatment","volume":"4","author":"Perez-Iglesias","year":"2010","journal-title":"Early Intervention in Psychiatry"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0172|cit172","unstructured":"Peuskens J Less weight gain with amisulpride: results from double-blind studies vs. risperidone and olanzapine Proceedings of the 16th European College of Neuropsychopharmacology Congress; 2003 Sep 20-24; Prague, Czech Republic 2003"},{"issue":"12","key":"10.1002\/14651858.CD006629.pub2-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1080\/00048670701689428","article-title":"Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme","volume":"41","author":"Poulin","year":"2007","journal-title":"Australian and New Zealand Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0174|cit174","doi-asserted-by":"crossref","unstructured":"Poyurovsky M Fuchs C Pashinian A Levi A Faragian S Maayan R Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study Proceedings of the 62nd Annual Scientific Meeting of the Society of Biological Psychiatry San Diego, CA Elsevier Science Inc 2007 129","DOI":"10.1007\/s00213-007-0731-1"},{"issue":"5","key":"10.1002\/14651858.CD006629.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1055\/s-0031-1280793","article-title":"Body mass index increase, serum leptin, adiponectin, neuropeptide y and lipid levels during treatment with olanzapine and haloperidol","volume":"44","author":"Raposo","year":"2011","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0176|cit176","first-page":"S99","article-title":"Pilot trial of contingency management for the treatment of antipsychotic-induced weight gain","volume":"1","author":"Ratliff","year":"2011","journal-title":"Obesity"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0177|cit177","first-page":"12","article-title":"Obesity, diabetes and hypertension associated with antipsychotic use in drug nave schizophrenia","volume":"1","author":"Saddichha","year":"2010","journal-title":"Australian and New Zealand Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD006629.pub2-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/13651500802155337","article-title":"Metabolic effects of olanzapine and risperidone in patients with psychotic disorders","volume":"12","author":"Safa","year":"2008","journal-title":"International Journal of Psychiatry in Clinical Practice"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0179|cit179","first-page":"276","article-title":"Preliminary data of metabolic risk at 6 months in subjects on antipsychotic agents: A 12-month randomized multi-centered trial","volume":"2","author":"Schneiderhan","year":"2011","journal-title":"Journal of Pharmacy Practice"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0180|cit180","unstructured":"Smith RC Kanellopoulou I Rachakonda S Lindenmayer J-P Davis JM Olanzapine vs. Risperidone effects on appetite and ghrelin in chronic schizophrenic patients Proceedings of the 49th Annual meeting of the Americam College of Neuropsychopharmacology; 2010 Dec 5-9; Miami, Florida 2010"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0181|cit181","first-page":"S315","article-title":"Olanzapine vs. Risperidone effects on appetite and ghrelin in chronic schizophrenic patients","volume":"35","author":"Smith","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0182|cit182","unstructured":"Spivak B Sibutramine for schizophrenia Stanley Foundation Research Programs 2009"},{"issue":"9","key":"10.1002\/14651858.CD006629.pub2-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1176\/appi.ajp.2011.10111609","article-title":"A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: Comparison of antipsychotics for metabolic problems (camp)","volume":"168","author":"Stroup","year":"2011","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0184|cit184","unstructured":"Stroup TS Hamer RM Ray N Esscok SM Lieberman JA The effect of switching from olanzapine, quetiapine, or risperidone to aripiprazole on risk of cardiovascular disease: Results from the comparison of antipsychotics for metabolic problems (camp) study Proceedings of the 50th Annual Meeting of the American College of Neuropsychopharmacology; 2011 Dec 4-8;a, Waikoloa, Hawaii 2011 S101"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0185|cit185","unstructured":"Sun J Ranitidine prevention and treatment of olanzapine-induced weight gain and glucose metabolism disorders Chinese Journal of Nervous and Mental Disorders [\u4e2d\u56fd\u795e\u7ecf\u7cbe\u795e\u75be\u75c5\u6742\u5fd7] 2007 560 2"},{"issue":"5","key":"10.1002\/14651858.CD006629.pub2-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/JCP.0b013e3181842586","article-title":"A randomized, open-label comparison of 2 switching strategies to aripiprazole treatment in patients with schizophrenia: add-on, wait, and tapering of previous antipsychotics versus add-on and simultaneous tapering","volume":"28","author":"Takeuchi","year":"2008","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0187|cit187","first-page":"927","article-title":"A comparison of the effects on lipid metabolic among four different atypical antipsychotic agents","volume":"6","author":"Tao","year":"2008","journal-title":"Journal of the Youjiang Medical College for Nationalities"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0188|cit188","first-page":"S181","article-title":"Low-dose naltrexone for antipsychotic-induced weight gain in women with schizophrenia","volume":"1","author":"Tek","year":"2011","journal-title":"Obesity"},{"issue":"18","key":"10.1002\/14651858.CD006629.pub2-BIB0189|cit189","first-page":"2119, 2122","article-title":"A comparative study of new antipsychopathic drugs lead to gain weight","volume":"20","author":"Tian","year":"2008","journal-title":"Medical Journal of Chinese People's Health [\u4e2d\u56fd\u6c11\u5eb7\u533b\u5b66]"},{"issue":"3","key":"10.1002\/14651858.CD006629.pub2-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/hup.1111","article-title":"Association study of polymorphisms in insulin induced gene 2 (insig2) with antipsychotic-induced weight gain in european and african-american schizophrenia patients","volume":"25","author":"Tiwari","year":"2010","journal-title":"Human Psychopharmacology"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0191|cit191","unstructured":"Uzcategui E EIFakih Y Rangel N Galeazzi T Baptista T Metformin plus sibutramine in the treatment of weight gain and metabolic dysfunction during olanzapine administration: a double-blind, placebo controlled pilot study Proceedings of the 160th Annual Meeting of the American Psychiatric Association; 2007 May 19-24; San Diego, CA 2007"},{"issue":"5","key":"10.1002\/14651858.CD006629.pub2-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1136\/ebm.13.5.146","article-title":"Metformin plus a lifestyle intervention was more effective than either alone for antipsychotic-induced weight gain: commentary","volume":"13","author":"Vaz-Leal","year":"2008","journal-title":"Evidence-Based Medicine"},{"issue":"18","key":"10.1002\/14651858.CD006629.pub2-BIB0193|cit193","first-page":"2117","article-title":"Behavioural intervention for antipsychotic caused weight gain","volume":"20","author":"Wang","year":"2008","journal-title":"Medical Journal of Chinese People's Health [\u4e2d\u56fd\u6c11\u5eb7\u533b\u5b66]"},{"issue":"1","key":"10.1002\/14651858.CD006629.pub2-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.schres.2012.02.021","article-title":"Metformin for treatment of antipsychotic-induced weight gain: A randomized, placebo-controlled study","volume":"138","author":"Wang","year":"2012","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0195|cit195","first-page":"29","article-title":"Effects of the cannabinoid-1 receptor antagonist rimonabant on satiety signaling in overweight people with schizophrenia: A randomized, double-blind pilot study","volume":"1","author":"Warren","year":"2011","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0196|cit196","unstructured":"Weiden P Radulovic L Wang C Allison D Sibutramine for the treatment of obesity in schizophrenia: randomized, placebo controlled pilot study Unpublished"},{"issue":"2-3","key":"10.1002\/14651858.CD006629.pub2-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.schres.2003.07.009","article-title":"Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia","volume":"66","author":"Harvey","year":"2004","journal-title":"Schizophrenia Research"},{"issue":"5","key":"10.1002\/14651858.CD006629.pub2-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/sj.npp.1301482","article-title":"Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone","volume":"33","author":"Weiden","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0199|cit199","unstructured":"Wirshing DA Erickson ZD Mena SJ Guzik LH Vesterman E Tran K Management of obesity associated with antipsychotic medication Proceedings of the World Psychiatric Association International congress; 2009 April 1-4th; Florence Italy 2009"},{"issue":"3","key":"10.1002\/14651858.CD006629.pub2-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1176\/appi.ajp.2007.07010079","article-title":"Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study","volume":"165","author":"Wu","year":"2008","journal-title":"American Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD006629.pub2-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1176\/appi.ajp.2008.165.4.540b","article-title":"Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study: correction","volume":"165","author":"Wu","year":"2008","journal-title":"American Journal of Psychiatry"},{"issue":"8","key":"10.1002\/14651858.CD006629.pub2-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1176\/appi.ajp.2012.11091432","article-title":"Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: A double-blind, randomized, placebo-controlled study","volume":"169","author":"Wu","year":"2012","journal-title":"American Journal of Psychiatry"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006629.pub2-BIB0203|cit203","first-page":"150","article-title":"Effects of 3-months trial of zonisamide and weight management program in obese schizophrenic inpatients","volume":"11","author":"Yoon","year":"2008","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0204|cit204","first-page":"288","article-title":"The effect of weight loss on obesity-related quality of life and body image in obese schizophrenic patients","volume":"1","author":"Yoon","year":"2009","journal-title":"Biological Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD006629.pub2-BIB0205|cit205","first-page":"396","article-title":"antipsychotic drugs on body mass of patients with schizophrenia and intervention] Google Translate","volume":"18","author":"Zhang","year":"2009","journal-title":"Chinese Journal of Pharmaco Epidemiology [\u836f\u7269\u6d41\u884c\u75c5\u5b66\u6742\u5fd7]"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0206|cit206","unstructured":"\u4f46\u96ea\u59e3 Quetiapine and clozapine on blood lipids, body weight control study [Google Translate] Journal of Chinese Rural Physician [\u4e2d\u56fd\u793e\u533a\u533b\u5e08\uff1a\u7efc\u5408\u7248] 2010 30"},{"issue":"06","key":"10.1002\/14651858.CD006629.pub2-BIB0207|cit207","first-page":"665","article-title":"Topiramate combined olanzapine Prevention second-generation antipsychotic-induced body weight and metabolic dysfunction","volume":"23","author":"\u5218\u5efa\u91d1","year":"2011","journal-title":"\u73b0\u4ee3\u5b9e\u7528\u533b\u5b66"},{"issue":"4","key":"10.1002\/14651858.CD006629.pub2-BIB0208|cit208","first-page":"244","article-title":"Influences on serum prolactin, blood glucose and body we ight for patients with first-episode schizophrenia treated with aripiprazole","volume":"19","author":"\u5218\u671d\u519b","year":"2009","journal-title":"Linchuang Jingshen Yixue Zazhi [\u4e34\u5e8a\u7cbe\u795e\u533b\u5b66\u6742\u5fd7]"},{"issue":"25","key":"10.1002\/14651858.CD006629.pub2-BIB0209|cit209","first-page":"9","article-title":"Systematic health education of diabetic patients with schizophrenia","volume":"16","author":"\u5218\u6839\u51e4","year":"2010","journal-title":"\u9f50\u9c81\u62a4\u7406\u6742\u5fd7"},{"issue":"6","key":"10.1002\/14651858.CD006629.pub2-BIB0210|cit210","first-page":"683","article-title":"Quetiapine and sulpiride on serum prolactin in schizophrenic patients and the impact of body weight [Google Translate]","volume":"16","author":"\u5218\u732e\u6807","year":"2010","journal-title":"Hebei Medicine [\u6cb3\u5317\u533b\u5b66]"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0211|cit211","unstructured":"\u54c8\u79c0\u82f1 \u6842\u68a6\u8354 \u738b\u6dd1\u83b2 Atypical antipsychotics caused weight gain in clinical research \u5b81\u590f\u533b\u5b66\u6742\u5fd7 2011 775 6"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0212|cit212","unstructured":"\u5d14\u5f00\u8273 \u5218\u5170\u82ac \u6768\u4e3d\u654f Ziprasidone and risperidone on prolactin in patients with schizophrenia and body mass, blood glucose, blood lipid [Google Translate] Shandong Archives of Psychiatry [\u5c71\u4e1c\u7cbe\u795e\u533b\u5b66] 2010 7 9"},{"issue":"5","key":"10.1002\/14651858.CD006629.pub2-BIB0213|cit213","first-page":"343","article-title":"Aripiprazole and risperidone on glucose and lipid [Google Translate]","volume":"19","author":"\u5f20\u4e1c\u536b","year":"2009","journal-title":"Linchuang Jingshen Yixue Zazhi [\u4e34\u5e8a\u7cbe\u795e\u533b\u5b66\u6742\u5fd7]"},{"issue":"06","key":"10.1002\/14651858.CD006629.pub2-BIB0214|cit214","first-page":"380","article-title":"Antipsychotics due to the intervention of the metabolic syndrome","volume":"20","author":"\u5f20\u534e\u5764","year":"2010","journal-title":"\u4e34\u5e8a\u7cbe\u795e\u533b\u5b66\u6742\u5fd7"},{"issue":"22","key":"10.1002\/14651858.CD006629.pub2-BIB0215|cit215","first-page":"2840","article-title":"Change-control study of ziprasidone and risperidone-induced weight and metabolic indicators","volume":"22","author":"\u5f20\u5cf0","year":"2010","journal-title":"\u4e2d\u56fd\u6c11\u5eb7\u533b\u5b66"},{"issue":"11","key":"10.1002\/14651858.CD006629.pub2-BIB0216|cit216","first-page":"1718","article-title":"Agengts treatment antipsychotics due to obesity","volume":"23","author":"\u5f6d\u6c38\u7ea2","year":"2008","journal-title":"Journal of Traditional Chinese Medicine [Chung i tsa chih ying wen pan][\u4e2d\u91ab\u96dc\u5fd7]"},{"issue":"04","key":"10.1002\/14651858.CD006629.pub2-BIB0217|cit217","first-page":"277","article-title":"Aripiprazole male schizophrenia patients with prolactin and blood sugar, weight","volume":"23","author":"\u638c\u6c38\u8389","year":"2010","journal-title":"\u7cbe\u795e\u533b\u5b66\u6742\u5fd7"},{"issue":"04","key":"10.1002\/14651858.CD006629.pub2-BIB0218|cit218","first-page":"384","article-title":"Controlled study of aripiprazole and olanzapine in the treatment of metabolic effects in patients with schizophrenia","volume":"9","author":"\u674e\u6653\u4e00","year":"2011","journal-title":"\u5168\u79d1\u533b\u5b66\u4e34\u5e8a\u4e0e\u6559\u80b2"},{"issue":"24","key":"10.1002\/14651858.CD006629.pub2-BIB0219|cit219","first-page":"1","article-title":"Three kinds of antipsychotic drugs on glucose metabolism in patients with schizophrenia [Google Translate]","volume":"15","author":"\u674e\u6881","year":"2009","journal-title":"\u5f53\u4ee3\u533b\u5b66"},{"issue":"8","key":"10.1002\/14651858.CD006629.pub2-BIB0220|cit220","first-page":"569","article-title":"Effects of 6-month aripiprazle, risperidone or clozapine treatment","volume":"23","author":"\u674e\u8f76\u741b","year":"2009","journal-title":"Chinese Mental Health Journal [\u4e2d\u56fd\u5fc3\u7406\u536b\u751f\u6742\u5fd7]"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0221|cit221","unstructured":"\u6768\u4e91\u79c0 The effect of nursing intervention in schizophrenia in patients with diabetes mellitus \u73b0\u4ee3\u4e2d\u897f\u533b\u7ed3\u5408\u6742\u5fd7 2011 2963 4"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0222|cit222","unstructured":"\u6768\u6625\u5f3a \u674e\u5b9d\u73e0 Aripiprazole and olanzapine on body weight, blood glucose control study effects [Google Translate] Linchuang Jingshen Yixue Zazhi [\u4e34\u5e8a\u7cbe\u795e\u533b\u5b66\u6742\u5fd7] 2009 339 40"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0223|cit223","unstructured":"\u6768\u8bda \u9676\u4e16\u6b66 \u9648\u5f3a \u6f58\u6da6\u5fb7 \u6f58\u5929\u4f1f \u674e\u6881 Association study of four kinds of antipsychotics and glucose metabolism in patients with schizophrenia and glycosylated hemoglobin \u4e2d\u56fd\u73b0\u4ee3\u533b\u5b66\u6742\u5fd7 2010 2816 20"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0224|cit224","unstructured":"\u6768\u96c0\u5c4f \u6731\u57f9\u4fca Affect control study of quetiapine and risperidone on serum prolactin Linchuang Jingshen Yixue Zazhi [\u4e34\u5e8a\u7cbe\u795e\u533b\u5b66\u6742\u5fd7] 2009 57 8"},{"issue":"1","key":"10.1002\/14651858.CD006629.pub2-BIB0225|cit225","first-page":"57","article-title":"Quetiapine and risperidone on serum prolactin control study [Google Translate]","volume":"19","author":"\u6768\u96c0\u5c4f","year":"2009","journal-title":"Linchuang Jingshen Yixue Zazhi [\u4e34\u5e8a\u7cbe\u795e\u533b\u5b66\u6742\u5fd7]"},{"issue":"1","key":"10.1002\/14651858.CD006629.pub2-BIB0226|cit226","first-page":"55","article-title":"Impact of antipsychotics on metabolic comparison","volume":"19","author":"\u6c6a\u536b\u534e","year":"2009","journal-title":"Linchuang Jingshen Yixue Zazhi [\u4e34\u5e8a\u7cbe\u795e\u533b\u5b66\u6742\u5fd7]"},{"issue":"1","key":"10.1002\/14651858.CD006629.pub2-BIB0227|cit227","first-page":"55","article-title":"Antipsychotics on metabolism [Google Translate]","volume":"19","author":"\u6c6a\u536b\u534e","year":"2009","journal-title":"Linchuang Jingshen Yixue Zazhi [\u4e34\u5e8a\u7cbe\u795e\u533b\u5b66\u6742\u5fd7]"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0228|cit228","unstructured":"\u738b\u79c0\u82b3 \u90ed\u7ea2\u4e3d \u5f20\u6d2a\u4f1f \u5434\u96ea\u98de \u5f20\u5efa Aripiprazole and ziprasidone, the prevalence of metabolic syndrome in patients with schizophrenia \u533b\u5b66\u4fe1\u606f(\u4e2d\u65ec\u520a) 2011 2570 1"},{"issue":"17","key":"10.1002\/14651858.CD006629.pub2-BIB0229|cit229","first-page":"8","article-title":"Three kinds of atypical antipsychotic drugs on lipid metabolism in patients with schizophrenia [Google Translate]","volume":"8","author":"\u767d\u9526\u6ce2","year":"2010","journal-title":"\u4e2d\u56fd\u533b\u836f\u6307\u5357"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0230|cit230","unstructured":"\u7f57\u4ea8\u5168 Oral Ou Lanning and risperidone cause significant weight gain in contrast observation [Google Translate] Journal of the Heze Medical College [\u83cf\u6cfd\u533b\u5b66\u4e13\u79d1\u5b66\u6821\u5b66\u62a5] 2010 21 2"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0231|cit231","unstructured":"\u803f\u5bd2\u677e \u5218\u8363\u82b9 \u8fb9\u8f9b\u4e11 \u82cf\u79c0\u8339 \u5d14\u6625\u9752 \u848b\u9f99 Comparative study of the effects of ariplprazole and risperidone on the therapeutic effect and patients\u2019weight in patients with schizophrenia Hebei Medical Journal 2009 407 9"},{"issue":"24","key":"10.1002\/14651858.CD006629.pub2-BIB0232|cit232","first-page":"15","article-title":"Three kinds of antipsychotic therapy on glucose and lipid metabolism in female first-episode schizophrenia and the impact of prolactin [Google Translate]","volume":"5","author":"\u949f\u6f47\u7426","year":"2010","journal-title":"\u4e2d\u56fd\u5b9e\u7528\u533b\u836f"},{"issue":"04","key":"10.1002\/14651858.CD006629.pub2-BIB0233|cit233","first-page":"198","article-title":"Metformin combined behavioral intervention therapy of clozapine in the treatment of schizophrenia in patients with body weight, blood glucose, blood lipids","volume":"23","author":"\u9648\u4fca\u96c4","year":"2010","journal-title":"\u56db\u5ddd\u7cbe\u795e\u536b\u751f"},{"issue":"9","key":"10.1002\/14651858.CD006629.pub2-BIB0234|cit234","first-page":"1238","article-title":"Four kinds of atypical antipsychotics on glucose and lipid metabolism in patients with schizophrenia [Google Translate]","volume":"31","author":"\u9676\u4e16\u6b66","year":"2009","journal-title":"Guangxi Medical Journal"},{"issue":"05","key":"10.1002\/14651858.CD006629.pub2-BIB0235|cit235","first-page":"365","article-title":"Four atypical antipsychotics, the prevalence of metabolic syndrome in patients with schizophrenia","volume":"23","author":"\u9676\u4e16\u6b66","year":"2010","journal-title":"\u7cbe\u795e\u533b\u5b66\u6742\u5fd7"},{"issue":"1","key":"10.1002\/14651858.CD006629.pub2-BIB0236|cit236","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0920-9964(03)80201-3","article-title":"Olanzapine causes greater increases in serum lipids than risperidone","volume":"60","author":"Tang","year":"2003","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0237|cit237","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2337\/diacare.27.2.596","article-title":"Consensus development conference on antipsychotic drugs and obesity and diabetes","volume":"27","author":"American Diabetes Association","year":"2004","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1002\/14651858.CD006629.pub2-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","article-title":"Antipsychotic-induced weight gain: a comprehensive research synthesis","volume":"156","author":"Allison","year":"1999","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1176\/appi.ps.54.4.565","article-title":"The impact of weight gain on quality of life among persons with schizophrenia","volume":"54","author":"Allison","year":"2003","journal-title":"Psychiatric Services"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecing skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0241|cit241","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3109\/10401230309085669","article-title":"Management of weight gain associated with antipsychotics","volume":"15","author":"Birt","year":"2003","journal-title":"Annals of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD006629.pub2-BIB0243|cit243","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"issue":"Suppl 7","key":"10.1002\/14651858.CD006629.pub2-BIB0244|cit244","first-page":"4","article-title":"Antipsychotic-induced weight gain and metabolic abnormalities: Implications for increased mortality in patients with schizophrenia","volume":"65","author":"Casey","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0245|cit245","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1046\/j.1039-8562.2003.02054.x","article-title":"Obesity in schizophrenia: What can be done about it?","volume":"12","author":"Catapana","year":"2004","journal-title":"Australasian Psychiatry"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0246|cit246","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1176\/ajp.2006.163.12.2090","article-title":"Effectiveness of switching antipsychotic medications","volume":"163","author":"Essock","year":"2006","journal-title":"American Journal of Psychiatry \u00a0\u00a0"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0247|cit247","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1177\/070674370404901106","article-title":"Characterizing coronary heart disease risk in chronic schizophrenia: High prevalence of the metabolic syndrome","volume":"49","author":"Cohn","year":"2004","journal-title":"Canadian Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0248|cit248","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1177\/070674370104600610","article-title":"Body mass index in persons with schizophrenia","volume":"46","author":"Coodin","year":"2001","journal-title":"Canadian Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0249|cit249","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1097\/01.nmd.0000100923.20188.2d","article-title":"Prevalence and correlates of obesity in a community sample of individuals with severe and persistent mental illness","volume":"191","author":"Daumit","year":"2003","journal-title":"Journal of Nervous and Mental Disease"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0250|cit250","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1080\/13651500510018310","article-title":"Belgian consensus on metabolic problems associated with atypical antipsychotics","volume":"9","author":"Nayer","year":"2005","journal-title":"International Journal of Psychiatry in Clinical Practice"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0251|cit251","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28th; Cape Town, South Africa 2000"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0253|cit253","volume-title":"At Least Five a Week. A Report From the Chief Medical Officer","author":"Department of Health","year":"2004"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomized trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0255|cit255","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD006629.pub2-BIB0256|cit256","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005148.pub2","article-title":"Interventions to reduce weight gain in schizophrenia.","author":"Faulkner","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0257|cit257","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.schres.2005.08.010","article-title":"A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls","volume":"80","author":"Goff","year":"2005","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0258|cit258","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0163-8343(00)00081-5","article-title":"Weight gain from novel antipsychotic drugs: Need for action","volume":"22","author":"Green","year":"2000","journal-title":"General Hospital Psychiatry"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0259|cit259","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the health survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0260|cit260","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0261|cit261","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.4088\/JCP.v66n0905","article-title":"Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: Results of a 10-year naturalistic study","volume":"66","author":"Henderson","year":"2005","journal-title":"Journal of Clinical Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD006629.pub2-BIB0262|cit262","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1345\/aph.1D423","article-title":"Current options in the management of olanzapine - associated weight gain","volume":"39","author":"Hester","year":"2005","journal-title":"Annals of Pharmacotherapy"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0263|cit263","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0264|cit264","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005] The Cochrane Library 2005"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0265|cit265","doi-asserted-by":"crossref","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009] The Cochrane Collaboration, 2009 Available from www.cochrane-handbook.org","DOI":"10.1002\/9780470712184"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0266|cit266","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0920-9964(01)00256-0","article-title":"Changes in body mass index for individuals with and without schizophrenia","volume":"55","author":"Homel","year":"2002","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0267|cit267","unstructured":"International Diabetic Federation IDF consensus worldwide definition of the metabolic syndrome http:\/\/www.idf.org\/webdata\/docs\/MetS_def_update2006.pdf 2006"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0268|cit268","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/bmj.323.7303.42","article-title":"Assessing the quality of controlled clinical trials","volume":"323","author":"J\u00fcni","year":"2001","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0269|cit269","volume-title":"Positive and Negative Syndrome Scale (PANSS) Manual","author":"Kay","year":"1986"},{"issue":"Suppl 7","key":"10.1002\/14651858.CD006629.pub2-BIB0270|cit270","first-page":"32","article-title":"The clinical implications of weight gain in schizophrenia","volume":"62","author":"Kurzthaler","year":"2001","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0271|cit271","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/003693300104600105","article-title":"Improving the physical health of patients with schizophrenia: Therapeutic nihilism or realism?","volume":"46","author":"Fevre","year":"2001","journal-title":"Scottish Medical Journal"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0272|cit272","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00125-004-1641-y","article-title":"Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: A cross-sectional study","volume":"48","author":"Mackin","year":"2005","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0273|cit273","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales - a major source of bias in randomised controlled trials of treatments for schizophrenia?","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0274|cit274","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1136\/ewjm.175.5.329","article-title":"The poor physical health of people with mental illness","volume":"175","author":"Osborn","year":"2001","journal-title":"Western Journal of Medicine"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0275|cit275","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.schres.2005.01.009","article-title":"The crossover approach to switching antipsychotics: What is the evidence?","volume":"76","author":"Remington","year":"2005","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0276|cit276","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1345\/aph.1C470","article-title":"Weight change after an atypical antipsychotic switch","volume":"37","author":"Ried","year":"October 2003","journal-title":"The Annals of Pharmacotherapy"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0277|cit277","doi-asserted-by":"crossref","first-page":"559","DOI":"10.4088\/JCP.v66n0503","article-title":"A 4-fold risk of metabolic syndrome in patients with schizophrenia: The Northern Finland 1966 birth cohort study","volume":"66","author":"Saari","year":"2005","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0278|cit278","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1192\/bjp.153.2.214","article-title":"Prevalence of obesity in patients receiving depot antipsychotics","volume":"153","author":"Silverstone","year":"1988","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0279|cit279","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0920-9964(02)00441-3","article-title":"Body mass index and quality of life in community-dwelling patients with schizophrenia","volume":"62","author":"Strassnig","year":"2003","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0280|cit280","doi-asserted-by":"crossref","first-page":"167","DOI":"10.4088\/JCP.v66n0203","article-title":"Obesity and associated complications in patients with severe mental illnesses: a cross-sectional survey","volume":"66","author":"Susce","year":"2005","journal-title":"Journal of Clinical Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD006629.pub2-BIB0281|cit281","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0282|cit282","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0920-9964(02)00498-X","article-title":"Obesity as a risk factor for antipsychotic noncompliance","volume":"66","author":"Weiden","year":"2004","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006629.pub2-BIB0283|cit283","unstructured":"Wikipedia Europoid http: \/\/en.wikipedia.org\/wiki\/Europoid"},{"issue":"Suppl 18","key":"10.1002\/14651858.CD006629.pub2-BIB0284|cit284","first-page":"13","article-title":"Schizophrenia and obesity: impact of antipsychotic medications","volume":"65","author":"Wirshing","year":"2004","journal-title":"Journal of Clinical Psychiatry"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD006629.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T09:29:57Z","timestamp":1723627797000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD006629.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2010,12,8]]},"references-count":284,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2013,2]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006629.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,8]]}}}